Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on the Safety and Effectiveness of tolDC for Patients with Relapsing Remitting and Progressive Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Spain
  • Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated Drugs:
    Belgium Bulgaria Czechia France Germany Greece +7
  • Study on Personalized Dosing of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands
  • Study on Frexalimab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Czechia France Germany Spain
  • Study on Clemastine and Fampridine for Patients with Multiple Sclerosis and Internuclear Ophthalmoparesis

    Not recruiting

    3 1 1
    Investigated Drugs:
    The Netherlands
  • Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    Austria Bulgaria Denmark France Germany Greece +5
  • Study on the Effectiveness of Tamsulosin for Treating Urinary Symptoms in Women with Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    France
  • Study on Amantadine and Transcranial Magnetic Stimulation for Reducing Fatigue in Multiple Sclerosis Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain
  • Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands
  • Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1 1
    Belgium Bulgaria Denmark France Germany Greece +5